-Reuters   The government has ordered a cut of nearly 20% in its 2014-15 healthcare budget due to fiscal strains, putting at risk key disease control initiatives in a country whose public spending on health is already among the lowest in the world. Two health ministry officials told Reuters on Tuesday that more than 60 billion rupees, or $948 million, has been slashed from their budget allocation of around $5 billion for the...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...

-Down to Earth Shortage of antiretroviral drugs and lack of diagnosis is not new in India, but government does not admit to the crisis The fight against HIV/AIDS in India is becoming tougher by the day as patients continue to face an acute shortage of antiretroviral drugs. This is an alarming situation for a country with the third-highest number of HIV+ people in the world-2.1 million. In 2012, about 140,000 people in...

-The Times of India NEW DELHI: Top selling medicine brands for stress, hypertension, HIV, pain and pneumonia may soon become cheaper. The drug price regulator National Pharmaceutical Pricing Authority (NPPA) is set to bring in at least 100 new drugs under price control to include combinations, dosages and strengths that are commonly prescribed by doctors and sold by pharmacists. For instance, currently only one strength of Paracetamol is under price control, whereas...

-The Indian Express The era of globalised markets is also an era of globalised sovereignties. Nation states must constantly sync their policies with global constituencies of policies and citizens. At times, domestic disharmony is the price nation states may be required and willing to pay. The case in point here is the proposed review of the intellectual property rights (IPR) policy, particularly those clauses that are related to pharmaceutical patent policy....